Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022672 (
acute tubular necrosis
)
2,175
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The chemokine
CX3CL1
plays a key role in glomerulonephritis and can act as both chemoattractant and adhesion molecule.
CX3CL1
also is upregulated in tubulointerstitial injury, but little is known about the subcellular distribution and function of
CX3CL1
in renal tubular epithelial cells (RTEC). Unexpectedly, it was found that
CX3CL1
is expressed predominantly on the apical surface of tubular epithelium in human renal transplant biopsy specimens with acute rejection or
acute tubular necrosis
. For studying the targeting of
CX3CL1
in polarized RTEC, MDCK cells that expressed untagged or green fluorescent protein-tagged
CX3CL1
were generated. The chemokine was present on the apical membrane and in subapical vesicles. Apical targeting of
CX3CL1
was not due to signals that were conferred by its intracellular domain, to associations with lipid rafts, or to O-glycosylation but, rather, depended on N-linked glycosylation of the protein. With the use of fluorescence recovery after photobleaching, it was found that
CX3CL1
is immobile in the apical membrane. However,
CX3CL1
partitioned with the triton-soluble rather than -insoluble cellular fraction, indicating that it is not associated directly with the actin cytoskeleton or with lipid rafts. Accordingly, disruption of rafts through cholesterol depletion did not render
CX3CL1
mobile. For exploration of potential functions of apical
CX3CL1
, binding of CX3CR1-expressing leukocytes to polarized RTEC was examined. Leukocyte adhesion to the luminal surface was enhanced significantly when
CX3CL1
was present. These data demonstrate that
CX3CL1
is expressed preferentially on the apical membrane of RTEC and suggest a novel function for the chemokine in recruitment and retention of leukocytes in tubulointerstitial inflammation.
...
PMID:Expression and targeting of CX3CL1 (fractalkine) in renal tubular epithelial cells. 1715 28
Chemokines and their receptors play an important role in the development of allograft rejection through directing mononuclear cell invasion of the graft. To study whether chemokine assays in the urine could prove to be predictive of acute rejection, we measured the urinary excretion of several chemokines, including
fractalkine
, chemokine monokine induced by interferon-gamma, interferon-gamma-inducible protein 10, macrophage inflammatory protein-3 alpha, granzyme B, and perforin in 215 allograft recipients and in 80 healthy control subjects. The 67 patients with acute rejection had significantly higher levels of all urinary chemokines compared to the healthy controls or patients having chronic allograft nephropathy but with stable renal function. Only changes in urinary
fractalkine
differentiated patients with acute rejection from those with
acute tubular necrosis
. The 7 patients who lost their grafts had greater urinary
fractalkine
, interferon-gamma, and macrophage inflammatory protein-3 alpha concentrations than those patients with reversible acute rejection. The area under the receiver operating characteristic curve for
fractalkine
was the best indicator among all of the markers differentiating 39 patients diagnosed with steroid-resistant from the 28 patients with steroid-sensitive acute rejection and in predicting graft loss. Our study shows that measuring urinary
fractalkine
levels is a noninvasive approach for detecting acute rejection where high levels were associated with steroid-resistance and poor outcome.
...
PMID:Urinary fractalkine is a marker of acute rejection. 1880 27